January 17, 2012
Study helps predict which lung cancer drugs most likely to work
Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer’s cells resistant to cancer drugs. The findings show that some classes of drugs won’t work, and certain types of so-called kinase inhibitors such as erlotinib may be the most effective at treating non–small cell lung cancers with those DNA changes. Some kinase inhibitors block a protein known as EGFR from directing cells to multiply.
In their paper published online Nov. 20 in Nature Structural & Molecular Biology, the researchers describe the molecular details of how some cancer drugs work.
“Some anti-cancer pharmaceuticals that we showed to be ineffective made it to clinical trials because they appeared to prevent the EGFR protein from sending growth signals,” said Philip A. Cole, the E.K. Marshall and Thomas H. Maren Professor of Pharmacology and Molecular Sciences and department director at the Johns Hopkins University School of Medicine. “But we found that different forms of EGFR protein reacted in unexpected ways, and by sorting out these forms in advance, we may be better able to determine which drugs will be better candidates for future clinical trials,” Cole said.
The researchers found that not all EGFR protein variations responded to the same drugs that normal EGFR protein did.
The scientists note that non–small cell lung cancer, the most common form of the disease, generally results from DNA changes in the EGFR gene, which normally controls cell growth. The genetic changes cause uncontrolled cell growth, the hallmark of cancer.
“Many clinical trials that used cetuximab and lapatinib were unsuccessful,” Cole said, “and our findings suggest why they failed and why erlotinib succeeded.”
The new discoveries were prompted by an effort to learn which drugs would work best in non–small cell lung cancer linked to EGFR protein alterations. To start, the researchers first tested cetuximab, a monoclonal antibody that prevents growth factors from binding EGFR. Cetuximab is currently used to treat head, neck and colon cancers, but researchers believed it could be a treatment for lung cancer, too.
They added the drug to purified EGFR protein—both normal and two altered versions that have been implicated in lung cancer—and measured the protein’s activity. Normal EGFR had a rate of growth-stimulating activity 100 times less when treated with cetuximab. Both altered EGFRs had much higher rates of growth-stimulating activity, 200 times more than normal EGFR when treated with cetuximab. The researchers concluded that while cetuximab does dampen the activity of normal EGFR protein, it does not significantly reduce the altered EGFR activity, which is not enough to stop cells from growing.
Because cetuximab was unsuccessful at blocking altered EGFR activity, the researchers tested kinase inhibitors—lapatinib, an FDA-approved breast cancer drug, and erlotinib, a drug currently used to treat non–small cell lung and pancreatic cancers. The researchers added different concentrations of lapatinib and erlotinib to the purified normal and altered EGFR proteins and measured the drugs’ effectiveness. Both erlotinib and lapatinib reduced normal EGFR activity, but lapatinib did not block altered EGFR activity. Erlotinib did appear to prevent altered EGFR from working, similar to the way it reduced the normal EGFR protein activity. This led the Johns Hopkins team to conclude that erlotinib is a better drug treatment for non–small cell lung cancers that are associated with altered forms of EGFR protein.
At Johns Hopkins, one of the senior investigators of the new study, Daniel Leahy, pioneered the procedure to isolate the EGFRs and another, Zhihong Wang, performed the experiments. Other authors of the paper, also from Johns Hopkins, are Patti Longo, Mary Katherine Tarrant, Kwangsoo Kim and Sarah Head.
Funding for this study was provided by grants from the National Institutes of Health.
Related websites
Pharmacology and Molecular Sciences